Study #2023-0159
A pilot study to assess the clinical utility of 18F-Fluciclovine (Axumin) PET-CT for detecting true- versus pseudo-progression of brain metastases on immunotherapy
MD Anderson Study Status
Enrolling
Treatment Agent
Diagnostic Test: 18F-Fluciclovine (Axumin), Diagnostic Test: Pet Scan
Description
To learn if 18F-Fluciclovine (Axumin) PET-CT scans can be used to better detect brain metastatic lesions in patients who are receiving immunotherapy.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Brain Metastases
Study phase:
Not applicable
Physician name:
Yang Lu
Department:
Nuclear Medicine
For general questions about clinical trials:
1-877-364-0962
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.